Royalty Report: Drugs, Vaccine, Therapeutic – Collection: 248399

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Vaccine
  • Therapeutic
  • Cancer
  • Delivery
  • Disease
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248399

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive license to use the Vaccine IP to further develop, manufacture, use, keep, import, export, supply or offer to supply, or, have a Partner manufacture, use, keep, import, export, supply or offer to supply, Plague Vaccine Doses to customers in performance of Supply Contracts.
License Property
Recombinant Yersinnia Pestis F1 and V (Plague) Protective Antigen Vaccine.

Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.

Patents are for Plague vacclnes and Vaccine Compositions.

Field of Use
The use in the United States is for the further development manufacture and supply of recombinant protective antigen plague vaccine doses.

The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.

IPSCIO Record ID: 248395

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products.
License Property
The Intellectual Property shall mean the Patents and knowhow, technical information and materials, including but not limited to cell lines, owned by the Licensor necessary or useful to develop, manufacture, have manufactured, import use, keep, sell and offer to sell the Plague Antigen and/or Vaccine.

Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.

Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.

Patents are for Plague Vaccines and Vaccine Compositions.

Field of Use
The field of use for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defense contracting procedures.

IPSCIO Record ID: 248394

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and to develop, make, have made, and use Anthrax Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
License Property
Anthrax Vaccine shall mean protective antigen from Bacillus anthracis (anthrax) which is produced using recombinant technology.

Anthrax Vaccine Dose shall mean the quantity of a formulation containing Anthrax Vaccine given to an individual in a single immunization.

Licensed Product shall mean an Anthrax Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

The patent is for Expression System (Anthrax Immuuogenic Polypeptide), a UK Priority Patent Application.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
These agreements allow for the licensing of certain patents and technology necessary to perform development of the rPA and rYP programs as required under the Company’s government contracts with the NIAID.

PharmAthene is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

IPSCIO Record ID: 249700

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, use, keep and sell or offer to sell Licensed Products.
License Property
The Licensed Product shall mean an Anthrax Vaccine Dose.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
The license field is for disease vaccines.

IPSCIO Record ID: 372631

License Grant
Licensor, the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare, grants to Licensee an exclusive license under the Licensed Patent Technology, with the right to grant and authorize sublicenses, to develop, to make, have made, import, use, have used, offer for sale, have sold and sell Licensed Products throughout the Licensed Territory in the Licensed Field of Use for the term of this Agreement, for the purpose of developing and commercializing a vaccine against B. antracis.
License Property
The patents are titled Asporogenic B, anthracis Expression System, and, Method of Making a Vaccine for Anthrax.
Field of Use
The Licensed Field of Use means applications or uses for the Licensed Patent Technology for human use as a vaccine for the prevention or treatment of anthrax infection.

IPSCIO Record ID: 230788

License Grant
Licensor grants an exclusive license in the Territory, including the right to grant sublicenses, to manufacture, use, sell, offer for sale, and import Products under all its right, title and interest in the Patent Rights.
License Property
Product means any animal vaccine or therapeutic agent the manufacture, use, sale, offer for sale or import of which would infringe any Valid Claim within Patent Rights in the absence of a license.

Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.

The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS  phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.

Field of Use
The field of use Area means research, development and commercialization with respect to animal vaccines and therapeutic agent as further described in the Research Plan.

IPSCIO Record ID: 279362

License Grant
The parties have agreed to enter an agreement for the Licensor of the United Kingdom to manufacture and supply products in the field of live or dead wild type attenuated or recombinant Listeria based vaccines to Licensee to undertake clinical trials and commercial sales in respect of such vaccines.

If Licensor is unwilling, or unable to supply and manufacture either Clinical Product or Bulk Product under the terms herein, Licensor will transfer the necessary Vaccine Process to enable a third party to manufacture and supply any part of the Clinical Product and/or Bulk Product to Licensee.

The parties have agreed that Licensor will have the right of first refusal to manufacture and supply Clinical Product and Bulk Product for use in the program of research and development, clinical trials and commercial exploitation.

License Property
Bulk Product means any and all Bulk Drug Substance, Drug Product and/or Programme Deliverable supplied by Licensor to Licensee under this Agreement for commercial use.

Clinical Product means the Programme Deliverable which is to be used in the development phase of the Programme and/or the Clinical Trials.

Vaccine Process means the process, methods, synthesis for making, using or exploiting the Drug Substance to produce the Drug Product for inclusion within the Programme Deliverable; .

Field of Use
The field of use is the field of live or dead cell based wild type or attenuated or recombinant Listeria vaccines with a therapeutic and/or preventative effect, for use in cancer and other indications.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 340468

License Grant
Licensor will grant to Licensee an exclusive (even as to Licensor except as necessary for Licensor to perform its obligation hereunder and under the Development Plan) , worldwide license including the right to sublicense through multiple tiers of sublicensees under the Licensed IP, to discover, develop, make, have made, use, sell, have sold, offer for sale, market, export, import and otherwise commercialize and exploit Products in the Field in the Territory.

Licensor will grant to Licensee an exclusive, worldwide license under Licensors rights in certain patents and related intellectual property, or the License, in which Licensee will receive certain rights relating to Licensor’s proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on proprietary vaccine technology involving a triple antigen virus like particle, or the Product.

License Property
Product shall mean any oral vaccines for COVID-19 and other novel coronaviruses utilizing the Licensee Technology for use in the Field that is integrated with or delivered by way of the Licensed IP under this Agreement.

Licensed IP means Patent Rights, Know-How and Information related to Licensor’s proprietary PODTM oral delivery technology involving a triple antigen virus like particle, or the Product.

The oral COVID-19 vaccine being developed promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).

Field of Use
Field shall encompass the vaccination against, and prevention, treatment, and management, of COVID-19 and any mutations thereof, and any other novel coronavirus and any mutations thereof after the Effective Date, and any symptoms related to the foregoing

Licensee is focused on the development of novel oral COVID-19 vaccines based on Licensor’s proprietary PODTM oral delivery technology as well as novel vaccine technology that was previously assigned to Licensee.

IPSCIO Record ID: 305790

License Grant
Under this license, Licensee received an exclusive, worldwide, royalty-bearing, sublicenseable license under Licensor’s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Licensor pursuant to the Licensor Supply Agreement.  Licensee is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions.
License Property
The vaccine compositions used the Licensors proprietary cell-free protein expression technology, known as XpressCF which utilizes extracts derived from strains of E. Coli.

Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.

The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.

Field of Use
The XpressCF platform is used in the field of vaccines to address infectious diseases in both human and animal use.

XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.

Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.